We are analyzing https://link.springer.com/article/10.1007/s11912-014-0404-2.

Title:
Optimal Treatment for Metastatic Bladder Cancer | Current Oncology Reports
Description:
Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the combination regimens gemcitabine–cisplatin and methotrexate–vinblastine–doxorubicin–cisplatin, are the standard first-line therapies. Second-line therapies have modest activity and no significant improvement in patient outcomes. Agents targeting growth, survival, and proliferation pathways have been added to cytotoxic therapy with limited added benefit to date. Modulating host immune response to cancer-associated antigens appears promising, with multiple new therapeutic approaches being pursued. Next-generation sequencing of invasive urothelial carcinoma has provided insights into the biology of this disease and potential actionable targets. Alterations in the receptor tyrosine kinase/Ras pathway and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway represent potential therapeutic targets in advanced disease, and novel agents are in development. Recent data from the Cancer Genome Atlas Research Network bladder cancer cohort and other efforts suggest that mutations in chromatin-regulatory genes are very common in invasive bladder tumors, and are more frequent than in other studied tumors. The discovery of new genomic alterations challenges drug development to change the course of this disease.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cancer, google, scholar, pubmed, article, urothelial, oncol, cas, phase, bladder, clin, carcinoma, advanced, metastatic, trial, patients, study, cisplatin, gemcitabine, treatment, chemotherapy, results, suppl, central, transitional, cell, paclitaxel, randomized, oncology, rosenberg, growth, therapy, factor, doxorubicin, iii, tract, group, everolimus, research, alterations, receptor, mvac, methotrexate, vinblastine, clinical, urol, carboplatin, privacy, cookies, content,

Topics {✒️}

month download article/chapter muscle-invasive bladder cancer targeted therapies von der maase muscle-invasive urothelial carcinoma high-risk urothelial cancer high-dose-intensity methotrexate advanced/metastatic bladder cancer high-grade bladder cancer platinum-resistant urothelial cancer metastatic transitional-cell carcinoma phosphatidylinositol 3-kinase/protein kinase fixed dose-rate gemcitabine nanoparticle albumin-bound paclitaxel cancer genome atlas long-term survival results full article pdf metastatic bladder cancer urothelial bladder cancer receive cisplatin-based chemotherapy siefker-radtke ao phase iii trial invasive bladder tumors invasive urothelial carcinoma metastatic urothelial cancer urothelial bladder carcinoma transitional cell cancer advanced bladder cancer bladder cancer cells recurrent molecular alterations metastatic urothelial carcinoma anderson cancer center transitional cell carcinoma privacy choices/manage cookies advanced urothelial cancer potential actionable targets comprehensive molecular characterization phase iii study actionable genomic alterations phase ii trial advanced urothelial carcinoma combination regimens gemcitabine–cisplatin agents targeting growth therapeutic approaches predictive markers bladder tumor history phase ii study supportive care versus garcia-grossman ir sternberg cn

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Optimal Treatment for Metastatic Bladder Cancer
         description:Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the combination regimens gemcitabine–cisplatin and methotrexate–vinblastine–doxorubicin–cisplatin, are the standard first-line therapies. Second-line therapies have modest activity and no significant improvement in patient outcomes. Agents targeting growth, survival, and proliferation pathways have been added to cytotoxic therapy with limited added benefit to date. Modulating host immune response to cancer-associated antigens appears promising, with multiple new therapeutic approaches being pursued. Next-generation sequencing of invasive urothelial carcinoma has provided insights into the biology of this disease and potential actionable targets. Alterations in the receptor tyrosine kinase/Ras pathway and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway represent potential therapeutic targets in advanced disease, and novel agents are in development. Recent data from the Cancer Genome Atlas Research Network bladder cancer cohort and other efforts suggest that mutations in chromatin-regulatory genes are very common in invasive bladder tumors, and are more frequent than in other studied tumors. The discovery of new genomic alterations challenges drug development to change the course of this disease.
         datePublished:2014-07-24T00:00:00Z
         dateModified:2014-07-24T00:00:00Z
         pageStart:1
         pageEnd:9
         sameAs:https://doi.org/10.1007/s11912-014-0404-2
         keywords:
            Metastatic bladder cancer
            Urothelial carcinoma
            Immunotherapeutics
            Molecular markers
            Targeted therapies
            Oncology
         image:
         isPartOf:
            name:Current Oncology Reports
            issn:
               1534-6269
               1523-3790
            volumeNumber:16
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Estrella M. Carballido
               affiliation:
                     name:Mayo Clinic Cancer Center
                     address:
                        name:Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jonathan E. Rosenberg
               affiliation:
                     name:Memorial Sloan Kettering Cancer Center
                     address:
                        name:Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
                        type:PostalAddress
                     type:Organization
                     name:Weill Cornell Medical College
                     address:
                        name:Weill Cornell Medical College, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Optimal Treatment for Metastatic Bladder Cancer
      description:Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the combination regimens gemcitabine–cisplatin and methotrexate–vinblastine–doxorubicin–cisplatin, are the standard first-line therapies. Second-line therapies have modest activity and no significant improvement in patient outcomes. Agents targeting growth, survival, and proliferation pathways have been added to cytotoxic therapy with limited added benefit to date. Modulating host immune response to cancer-associated antigens appears promising, with multiple new therapeutic approaches being pursued. Next-generation sequencing of invasive urothelial carcinoma has provided insights into the biology of this disease and potential actionable targets. Alterations in the receptor tyrosine kinase/Ras pathway and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway represent potential therapeutic targets in advanced disease, and novel agents are in development. Recent data from the Cancer Genome Atlas Research Network bladder cancer cohort and other efforts suggest that mutations in chromatin-regulatory genes are very common in invasive bladder tumors, and are more frequent than in other studied tumors. The discovery of new genomic alterations challenges drug development to change the course of this disease.
      datePublished:2014-07-24T00:00:00Z
      dateModified:2014-07-24T00:00:00Z
      pageStart:1
      pageEnd:9
      sameAs:https://doi.org/10.1007/s11912-014-0404-2
      keywords:
         Metastatic bladder cancer
         Urothelial carcinoma
         Immunotherapeutics
         Molecular markers
         Targeted therapies
         Oncology
      image:
      isPartOf:
         name:Current Oncology Reports
         issn:
            1534-6269
            1523-3790
         volumeNumber:16
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Estrella M. Carballido
            affiliation:
                  name:Mayo Clinic Cancer Center
                  address:
                     name:Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jonathan E. Rosenberg
            affiliation:
                  name:Memorial Sloan Kettering Cancer Center
                  address:
                     name:Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
                     type:PostalAddress
                  type:Organization
                  name:Weill Cornell Medical College
                  address:
                     name:Weill Cornell Medical College, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Oncology Reports
      issn:
         1534-6269
         1523-3790
      volumeNumber:16
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Mayo Clinic Cancer Center
      address:
         name:Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, USA
         type:PostalAddress
      name:Memorial Sloan Kettering Cancer Center
      address:
         name:Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
         type:PostalAddress
      name:Weill Cornell Medical College
      address:
         name:Weill Cornell Medical College, New York, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Estrella M. Carballido
      affiliation:
            name:Mayo Clinic Cancer Center
            address:
               name:Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jonathan E. Rosenberg
      affiliation:
            name:Memorial Sloan Kettering Cancer Center
            address:
               name:Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
               type:PostalAddress
            type:Organization
            name:Weill Cornell Medical College
            address:
               name:Weill Cornell Medical College, New York, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, USA
      name:Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
      name:Weill Cornell Medical College, New York, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(201)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.02s.

LINK . SPRINGER . COM {}